Skip to main content

⚠️ Research Use Only — Compounds discussed are research chemicals, not FDA-approved for human use. Not medical advice. Full disclaimers →

PeptiDex
  • Library
  • Stacks
  • Tools
  • Vendors
  • Coupons
  • Blog
  • About
Start
§ Stay Current

The Peptide Brief.

Bi-weekly research updates, vendor news, and editorial analysis. No spam.

No spam. Unsubscribe anytime. We respect your inbox.

PeptiDex

The independent, evidence-based peptide research index. Trusted by researchers worldwide for unbiased education and verified sourcing.

§ Learn

  • Peptide 101
  • Library
  • Evidence Dashboard
  • Blog
  • FAQ

§ Tools

  • Cycle Planner
  • Evidence Dashboard
  • Peptide Comparison
  • Price Comparison
  • Reconstitution Calc
  • COA Analyzer

§ Source

  • Vendor Reviews
  • Amino Club Review
  • COA Library
  • Peptide Stacks

§ About

  • Our Mission
  • Editorial Policy
  • Medical Disclaimer
  • Contact
Last reviewed: June 3, 2026 · PeptiDex Editorial Team
© 2026 PeptiDex. All rights reserved.
PrivacyTermsDisclosures
⚠️ Research Compound — FOXO4-DRI is a research chemical. It is not FDA-approved for human therapeutic use. Information on this page reflects published research literature and is not medical advice. Do not use without licensed medical supervision. [Full disclaimers]
Home/Library/FOXO4-DRI

FOXO4-DRI

PeptiDex Research
Last reviewed June 3, 2026

Also known as: FOXO4-D-Retro-Inverso, Senolytic peptide

Quick Answer

FOXO4-DRI is a senolytic peptide research compound (not FDA-approved for human use) studied for senescent cell elimination (senolytics). FOXO4-DRI is a senolytic peptide that forces senescent ('zombie') cells to undergo programmed death by breaking the survival signal that keeps them alive, studied in mice for tissue rejuvenation and reversal of aging markers. Research dose: 5–10 mg pulsed — 3 days per week, per mouse study protocol. Half-life: 2 hours. Available from COA-verified vendors with code PEPTIDEX for up to 20% off.

Where to Source
Ranked by $/mg
1Bio Longevity Labs Best $/mg
$233.72
$274.97Save $41.25
10mg vial
$27.50/mg
99%+ purityTested May 2026
Use code for 15% off:
Shop Bio Longevity Labs
Compare all 1 vendors →

Rankings independent · Research use only

D-retro-inverso peptide that disrupts the interaction between FOXO4 and p53 in senescent cells. In normal cells, FOXO4 retains p53 in the nucleus preventing apoptosis — a mechanism senescent cells exp

Senolytic Peptide
Half-life: 2 hours
1 studies indexed
Updated: April 2026

Where to Buy FOXO4-DRI

COA-verified vendors · Use code PEPTIDEX for up to 20% off

* Prices for research peptide acquisition. Not therapeutic products.

VendorPurityList PriceWith PEPTIDEXCodeShop
Bio Longevity LabsTriple-Tested
99%+$274.9710 mg
$233.72Save 15%
PEPTIDEX

* Research vendor — verify your regional regulations before purchase.

Shop
Bio Longevity LabsTriple-Tested
$274.97 · 10 mg$233.72−15%

Use code PEPTIDEX for 15% off at Bio Longevity Labs.

* Research vendor — verify your regional regulations before purchase.

Shop at Bio Longevity Labs

§ Mechanism of Action

D-retro-inverso peptide that disrupts the interaction between FOXO4 and p53 in senescent cells. In normal cells, FOXO4 retains p53 in the nucleus preventing apoptosis — a mechanism senescent cells exploit for survival. FOXO4-DRI competitively binds FOXO4, freeing p53 to migrate to mitochondria, triggering apoptosis selectively in senescent cells. Results in clearance of senescent cell burden, reduction of the senescence-associated secretory phenotype (SASP), and tissue rejuvenation markers in aged mice.

§ Primary Benefits

  1. 1Senescent cell elimination (senolytics)
  2. 2longevity
  3. 3tissue rejuvenation
  4. 4SASP reduction

§ Clinical Evidence

Targeted apoptosis of senescent cells restores tissue homeostasis during chemotoxic syndromes

Baar et al. (Cell): FOXO4-DRI selectively induces apoptosis in senescent cells in vivo, restoring fur density, fitness, and renal function in aged and chemotherapy-treated mice without detectable toxicity to non-senescent tissues.

Preclinical

§ Safety Profile

⚠ EXPERIMENTAL COMPOUND. NO HUMAN CLINICAL TRIALS. Mechanism is potent and irreversible (apoptosis induction). Selective for senescent cells in mouse models but human selectivity profiles are unknown. Aggressive Herxheimer-like inflammatory response from SASP release possible during senescent cell clearance. DO NOT USE without comprehensive medical supervision.

See our evidence grading methodology for how we evaluate and grade peptide safety data.

§ Dosing Protocol

* Dosing data from published literature — not a human use recommendation.

RouteSubQ
Dose Range5000–10000 mcg
FrequencyPulsed — 3 days per week, per mouse study protocol
Cycle Length3–3 weeks

Mouse study: 10mg/kg IP 3x/week. No validated human protocol. Human equivalent dose extrapolation is not clinically validated.

§ Pharmacokinetics

⏱️ Half-Life: 2h

Plasma concentration over time
100%50%0%0t½ = 2h

§ Expected Outcomes

Week 1

Senescent cell clearance begins; possible SASP-driven inflammatory response

Weeks 2–4

Tissue rejuvenation markers in mouse models (fur density, fitness scores)

§ Adverse Effects

Side EffectIncidenceSeverity

SASP inflammatory response

Transient cytokine surge from dying senescent cells

Unknown in humansmoderate

Unknown off-target apoptosis

Selective for senescent cells in mouse models; human selectivity uncharacterized

Unknownrare

Incidence rates sourced from published clinical trial data where available; otherwise based on community research observations.

Where to Source FOXO4-DRI for Research

Finding verified, high-purity FOXO4-DRI requires rigorous COA verification. We independently evaluate vendors based on third-party HPLC testing, purity thresholds (≥98%), and batch-specific documentation.

View COA-Verified FOXO4-DRI

✓ Third-party tested·✓ US shipping·✓ COA on every batch

Disclosure: PeptiDex may earn a commission from purchases made through affiliate links. This does not affect our editorial independence or recommendations. We exclusively feature vendors that pass our strict quality verification protocols.

PEPTIDEX coupon for FOXO4-DRISave 20% on FOXO4-DRI at Amino Club & verified vendors →
Reconstitution CalculatorCalculate reconstitution for FOXO4-DRI →
Compare ToolCompare FOXO4-DRI to similar peptides →

Frequently Asked Questions

Cite This Page

PeptiDex. (2026). FOXO4-DRI. PeptiDex Research Platform. https://peptidex.app/library/foxo4-dri

For academic and research purposes.

⚠️ Educational only · Not medical advice · For research use only. Information on this page is compiled from peer-reviewed literature and is intended strictly for educational and informational purposes. Peptides discussed may be unapproved research chemicals — consult a licensed healthcare professional before considering any peptide compound. Read our full disclaimer

Affiliate disclosure: PeptiDex may earn commissions from purchases made through vendor links on this page. This does not affect our editorial ranking or vendor recommendations — we exclusively feature vendors that pass independent COA verification. See our methodology · Editorial policy

Free Download

2026 Peptide Stack Cheat Sheet

12stacks • exact dosages • cycle lengths • printable reference

No spam. Unsubscribe anytime.

Where to Source
Ranked by $/mg
1Bio Longevity Labs Best $/mg
$233.72
$274.97Save $41.25
10mg vial
$27.50/mg
99%+ purityTested May 2026
Use code for 15% off:
Shop Bio Longevity Labs
Compare all 1 vendors →

Rankings independent · Research use only

§ Quick Reference

CategorySenolytic Peptide
Half-Life2 hours
RouteSubQ
Dose5000–10000 mcg
Studies1
FDAResearch Only

§ On This Page

  • How It Works
  • Benefits
  • Key Studies
  • Safety Notes
  • Dosing Protocol
  • Half-Life
  • Timeline
  • Side Effects
§ About the Author Verified
PeptiDex Research — independent peptide research project

PeptiDex Research

Independent researcher, not a medical professional

PeptiDex Research is the byline used by the independent researcher who builds and maintains PeptiDex. The site is a one-person research project — there is no editorial board, no medical reviewers, and no clinical staff. Content is produced by reading...

View profile
Last fact-checked: June 3, 2026 · PeptiDex Editorial Team